找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cell Culture Engineering and Technology; In appreciation to P Ralf P?rtner Book 2021 The Editor(s) (if applicable) and The Author(s), under

[復制鏈接]
樓主: Autopsy
11#
發(fā)表于 2025-3-23 11:31:15 | 只看該作者
12#
發(fā)表于 2025-3-23 14:36:51 | 只看該作者
Practical Considerations for the Scale-Up of Chinese Hamster Ovary (CHO) Cell Cultures the fastest-growing segment of the global biopharmaceutical market. During process development, scale-up is done stepwise from micro-bioreactors or shake flasks, to benchtop bioreactors, passing by pilot-scale platforms before finally being implemented in industrial-scale vessels. However, achievin
13#
發(fā)表于 2025-3-23 21:19:10 | 只看該作者
Intensified and Continuous mAb Production with Single-Use Systemsic and autoimmune diseases. Their commercial production processes are mainly based on Chinese hamster ovary (CHO) suspension cells, which are currently cultivated in fed-batch mode at cubic meter scale. The annually growing market for therapeutic mAbs and the pressure on producers to reduce their ma
14#
發(fā)表于 2025-3-24 00:22:13 | 只看該作者
Mathematical Modelling of Cell Culture Processesdels can be used to simulate mammalian cells. Modelling of bioprocesses largely benefit from including kinetics, which reflects the influence of metabolites or other factors on the process variables. Due to the complexity of the kinetic models, with the challenges of determining the kinetic equation
15#
發(fā)表于 2025-3-24 04:13:41 | 只看該作者
16#
發(fā)表于 2025-3-24 09:55:49 | 只看該作者
Filtering of spatio-temporal fields, these challenges. This chapter describes the current and future cell engineering strategies to achieve high therapeutic protein productivity with desired product quality in biotechnologically important mammalian cell lines.
17#
發(fā)表于 2025-3-24 13:30:22 | 只看該作者
18#
發(fā)表于 2025-3-24 18:40:34 | 只看該作者
Next-Generation Cell Engineering Platform for Improving Recombinant Protein Production in Mammalian these challenges. This chapter describes the current and future cell engineering strategies to achieve high therapeutic protein productivity with desired product quality in biotechnologically important mammalian cell lines.
19#
發(fā)表于 2025-3-24 21:54:40 | 只看該作者
20#
發(fā)表于 2025-3-25 02:09:08 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2026-1-21 08:18
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
青龙| 轮台县| 南川市| 阿拉善右旗| 伊金霍洛旗| 永川市| 明溪县| 城口县| 邵武市| 和田市| 本溪| 莲花县| 道真| 大厂| 大庆市| 深泽县| 长兴县| 拉萨市| 清水县| 宣威市| 大新县| 吴堡县| 平远县| 吕梁市| 鹤峰县| 固阳县| 汶上县| 合阳县| 三河市| 阳信县| 阜城县| 洞头县| 合川市| 岳池县| 淮北市| 泉州市| 安徽省| 上高县| 莒南县| 凤城市| 永春县|